Literature DB >> 8619817

The expression of truncated MK in human tumors.

T Kaname1, K Kadomatsu, K Aridome, S Yamashita, K Sakamoto, M Ogawa, T Muramatsu, K Yamamura.   

Abstract

Midkine (MK) is a heparin binding growth/differentiation factor different from fibroblast growth factors (FGFs), and is largely composed of two domains which are found by a folded polypeptide chain interconnected by disulfide bridges. Polymerase chain reaction revealed the presence of a short MK mRNA in 7 among 12 human tumor cells which expressed MK mRNA. All of 4 pancreatic carcinoma cell lines expressed the short species in addition to the full size mRNA. The short mRNA lacked an exon and resulted in the lack of a more N-terminally located domain. The truncated form of MK was found also in some surgically removed specimens of human tumors, but not in noncancerous tissue.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8619817     DOI: 10.1006/bbrc.1996.0214

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

Review 1.  Structure and function of midkine as the basis of its pharmacological effects.

Authors:  T Muramatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 2.  Pancreatic cancer.

Authors:  C Güngör; B T Hofmann; G Wolters-Eisfeld; M Bockhorn
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

3.  Inhibitory effect of midkine-binding peptide on tumor proliferation and migration.

Authors:  Hui-Lian Huang; Jian-Fen Shen; Li-Shan Min; Jin-Liang Ping; Yong-Liang Lu; Li-Cheng Dai
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

4.  Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus.

Authors:  Shuji Kubo; Yoshiko Kawasaki; Norie Yamaoka; Masatoshi Tagawa; Noriyuki Kasahara; Nobuyuki Terada; Haruki Okamura
Journal:  J Gene Med       Date:  2010-08       Impact factor: 4.565

Review 5.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

6.  Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.

Authors:  M Takagi-Kimura; T Yamano; M Tagawa; S Kubo
Journal:  Cancer Gene Ther       Date:  2014-02-28       Impact factor: 5.987

7.  Over-expressed and truncated midkines promote proliferation of BGC823 cells in vitro and tumor growth in vivo.

Authors:  Qing-Ling Wang; Hui Wang; Shu-Li Zhao; Ya-Hong Huang; Ya-Yi Hou
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

8.  Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.

Authors:  Misato Takagi-Kimura; Tomoki Yamano; Atsuko Tamamoto; Nobutaka Okamura; Haruki Okamura; Tomoko Hashimoto-Tamaoki; Masatoshi Tagawa; Noriyuki Kasahara; Shuji Kubo
Journal:  Cancer Sci       Date:  2013-09-23       Impact factor: 6.716

9.  Midkine mRNA is overexpressed in pancreatic cancer.

Authors:  Seiji Ohhashi; Kenoki Ohuchida; Kazuhiro Mizumoto; Takuya Egami; Jun Yu; Lin Cui; Hiroki Toma; Shunichi Takahata; Toshinaga Nabae; Masao Tanaka
Journal:  Dig Dis Sci       Date:  2008-08-21       Impact factor: 3.199

Review 10.  Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases.

Authors:  Takashi Muramatsu
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.